FVB-Abcb4 KO Mouse
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
FVB-Abcb4 KO Mouse
Product Name
FVB-Abcb4 KO Mouse
Product ID
C001590
Strain Name
FVB/NJCya-Abcb4em1/Cya
Backgroud
FVB/NJCya
When using this mouse strain in a publication, please cite “FVB-Abcb4 KO Mouse (Catalog C001590) were purchased from Cyagen.”
Disease Animal Models
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Disease Animal Models
Basic Information
Validation Data
Related Resource
Basic Information
Gene Name
Gene Alias
Mdr2, Pgy2, Pgy-2, mdr-2
NCBI ID
Chromosome
Chr 5
MGI ID
Datasheet
Strain Description
Progressive Familial Intrahepatic Cholestasis Type 3 (PFIC3) is a rare, life-threatening autosomal recessive hereditary liver disease caused by mutations in the ABCB4 gene (also known as MDR3 in humans and MDR2 in rodents) [1-3]. The disease is characterized by early persistent cholestasis, leading to the accumulation of bile acids in the liver and subsequent hepatocellular damage. Clinical manifestations of PFIC3 include jaundice (yellowing of the skin and eyes), pruritus, fatigue, and growth failure. If untreated, it can progress to cirrhosis and liver failure in early childhood [4]. The ABCB4 gene encodes Multidrug Resistance Protein 3 (MDR3), a member of the ATP-binding cassette (ABC) transporter family, which is a liver-specific phosphatidylcholine (PC) transporter [5]. MDR3 is primarily expressed on the canalicular membrane of hepatocytes (the membrane that forms bile canaliculi). It is involved in the transport of phosphatidylcholine from the hepatocyte membrane to vesicles, which are then secreted into bile, forming PC-cholesterol vesicles and a small number of mixed bile salt micelles [6]. Mutations in ABCB4 lead to the loss or dysfunction of MDR3, reducing PC levels in bile, destabilizing micelles, and increasing bile salt concentrations, thereby causing cholestasis and hepatocellular injury [7].
Studies have shown that knocking out the Abcb4 gene in mice leads to a phenotype similar to human PFIC3, although the severity and progression of the disease vary across different mouse strains. In the commonly used C57BL/6 background, Abcb4-KO mice exhibit a relatively mild pathological phenotype due to lower bile salt toxicity, and a diet enriched in hydrophobic bile salts is typically required to induce a more human-like PFIC3 phenotype [8-10]. In contrast, Abcb4-KO mice in the FVB background naturally exhibit most of the biomarkers and pathological features of human PFIC3, including hepatomegaly, liver fibrosis, and early disease onset with more severe progression [10-11].
Cyagen has generated the FVB-Abcb4 KO mouse model by knocking out the Abcb4 gene in FVB mice. This model lacks the Abcb4 gene and protein expression and exhibits liver enlargement, elevated liver function markers, and increased total bilirubin. Histopathological examination shows hepatocyte necrosis, inflammatory cell infiltration, connective tissue proliferation, bile duct proliferation, and liver fibrosis.
Reference
Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis. 2009 Jan 8;4:1.
Vij M, Safwan M, Shanmugam NP, Rela M. Liver pathology in severe multidrug resistant 3 protein deficiency: a series of 10 pediatric cases. Ann Diagn Pathol. 2015 Oct;19(5):277-82.
de Vree JM, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, Deleuze JF, Desrochers M, Burdelski M, Bernard O, Oude Elferink RP, Hadchouel M. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):282-7.
Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell. 1993 Nov 5;75(3):451-62.
Delaunay JL, Durand-Schneider AM, Dossier C, Falguières T, Gautherot J, Davit-Spraul A, Aït-Slimane T, Housset C, Jacquemin E, Maurice M. A functional classification of ABCB4 variations causing progressive familial intrahepatic cholestasis type 3. Hepatology. 2016 May;63(5):1620-31.
Oude Elferink RP, Paulusma CC, Groen AK. Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases. Gastroenterology. 2006 Mar;130(3):908-25.
Morotti RA, Suchy FJ, Magid MS. Progressive familial intrahepatic cholestasis (PFIC) type 1, 2, and 3: a review of the liver pathology findings. Semin Liver Dis. 2011 Feb;31(1):3-10.
Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell. 1993 Nov 5;75(3):451-62.
Ikenaga N, Liu SB, Sverdlov DY, Yoshida S, Nasser I, Ke Q, Kang PM, Popov Y. A new Mdr2(-/-) mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer. Am J Pathol. 2015 Feb;185(2):325-34.
Weber ND, Odriozola L, Martínez-García J, Ferrer V, Douar A, Bénichou B, González-Aseguinolaza G, Smerdou C. Gene therapy for progressive familial intrahepatic cholestasis type 3 in a clinically relevant mouse model. Nat Commun. 2019 Dec 13;10(1):5694.
Aronson SJ, Bakker RS, Shi X, Duijst S, Ten Bloemendaal L, de Waart DR, Verheij J, Ronzitti G, Oude Elferink RP, Beuers U, Paulusma CC, Bosma PJ. Liver-directed gene therapy results in long-term correction of progressive familial intrahepatic cholestasis type 3 in mice.
Strain Strategy
The Abcb4 gene in FVB mice is knocked out by targeting exons 9 to 12 using gene editing techniques.

Figure 1. Gene editing strategy for FVB-Abcb4 KO mice.
Application Area
Study of Multidrug Resistance Protein 3 (MDR3) function;
Mechanistic studies of Progressive Familial Intrahepatic Cholestasis Type 3 (PFIC3);
Drug development, screening, and preclinical efficacy evaluation for PFIC3 treatment.
Validation Data
Related Resource
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
